138
Views
30
CrossRef citations to date
0
Altmetric
Original Research

Integrated analysis reveals key genes with prognostic value in lung adenocarcinoma

, , &
Pages 6097-6108 | Published online: 21 Nov 2018

Abstract

Background

Lung cancer is one of the most common malignant tumors. Despite advances in lung cancer therapies, prognosis of non-small-cell lung cancer is still unfavorable. The aim of this study was to identify the prognostic value of key genes in lung tumorigenesis.

Methods

Differentially expressed genes (DEGs) were screened out by GEO2R from three Gene Expression Omnibus cohorts. Common DEGs were selected for Kyoto Encyclopedia of Genes and Genomes pathway analysis and Gene Ontology enrichment analysis. Protein– protein interaction networks were constructed by the STRING database and visualized by Cytoscape software. Hub genes, filtered from the CytoHubba, were validated using the Gene Expression Profiling Interactive Analysis database, and their genomic alterations were identified by performing the cBioportal. Finally, overall survival analysis of hub genes was performed using Kaplan–Meier Plotter.

Results

From three datasets, 169 DEGs (70 upregulated and 99 downregulated) were identified. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses showed that upregulated DEGs were significantly enriched in cell cycle, p53 pathway, and extracellular matrix–receptor interactions; the downregulated DEGs were significantly enriched in PPAR pathway and tyrosine metabolism. The protein–protein interaction network consisted of 71 nodes and 305 edges, including 49 upregulated and 22 downregulated genes. The hub genes, including AURKB, BUB1B, KIF2C, HMMR, CENPF, and CENPU, were overexpressed compared with the normal group by Gene Expression Profiling Interactive Analysis analysis, and associated with reduced overall survival in lung cancer patients. In the genomic alterations analysis, two hotspot mutations (S2021C/F and E314K/V) were identified in Pfam protein domains.

Conclusion

DEGs, including AURKB, BUB1B, KIF2C, HMMR, CENPF, and CENPU, might be potential biomarkers for the prognosis and treatment of lung adenocarcinoma.

Introduction

Lung cancer is the leading cause of cancer-related death in men and the second leading cause in women worldwide; it is also the most common cause of cancer death in both men and women in the United States.Citation1 Lung cancer is classified as small-cell or non-small-cell lung cancer (NSCLC) for the purposes of treatment. NSCLC constitutes about 85% of all lung cancers, and lung adenocarcinoma (LAC) is the most diagnosed histological subtype of NSCLC, followed by squamous cell carcinoma. The high incidence of lung cancer is due to tobacco smoking, indoor air pollution,Citation2 outdoor pollution,Citation3 genetic alterations,Citation4 and other factors. The genetic alterations associated with lung cancer include epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) fusion or rearrangement,Citation5,Citation6 and other aberrations. Targeted therapy, such as tyrosine-kinase inhibitors can suppress the kinase activity of oncogenic EGFR and ALK proteins.Citation7 Despite advances in chemotherapy, radiation therapy, surgery, and targeted therapy for lung cancer, the 5-year survival rates for NSCLC are only 21%.Citation8 Therefore, it is important to investigate molecular mechanisms and biomarkers in LAC to develop more effective diagnostic and therapeutic strategies.

Through the rapid development of molecular biology and bioinformatics, such as microarray technology – a high-throughput platform for gene expression analysis – we can now explore differentially expressed genes (DEGs) involved in tumorigenesis. For example, through a comprehensive bioinformatics analysis, Shi et alCitation9 identified that CDCA2 was dramatically upregulated in LAC tissues, where it promotes proliferation and predicts poor prognosis.Citation9 Zhang et alCitation10 demonstrated that HOXA11–AS overexpression was associated with lung cancer development and progression also using an integrated bioinformatics analysis. Li et alCitation11 found that CD44 overexpression was associated with the occurrence and migration of NSCLC using a combined bioinformatics technology. Despite the recent advances in targeted therapies for lung cancer, including agents targeting EGFR, VEGF, and ALK, organometallics and antimitotics are still largely used for treatment.Citation12 Thus, more work is needed to discover the underlying molecular mechanisms in lung cancer.

In this study, we identified key genes in LAC by combining bioinformatics analyses. DEGs, Gene Ontology (GO) terms, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways associated with lung cancer were investigated. Subsequently, the expression of key genes related to lung cancer was validated. Furthermore, survival analyses correlated with the expression of the key genes were carried out. We investigated the potential candidate biomarkers for their utility in diagnosis, prognosis, and drug targeting in LAC.

Materials and methods

Microarray data

Three gene expression profiles GSE18842, GSE21933, and GSE89039 were downloaded from the National Center for Biotechnology Information Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo) database. GSE18842 included 46 NSCLC tissue samples and 45 paired nontumor samples. GSE21933 consisted of 21 NSCLC tissue samples and 21 corresponding normal samples. GSE89039 comprised eight LAC tissues samples and eight corresponding nontumor samples.

DEG screening

GEO2R (http://www.ncbi.nlm.nih.gov/geo/geo2r/) is an interactive web tool that compares two groups of samples under the same experimental conditions and can analyze almost any GEO series.Citation13 This tool uses established Bioconductor R packages to analyze GEO data. In this study, GEO2R was used to screen DEGs between lung cancer and normal tissue samples. An adjusted P-value (adj. P) <0.05 and |logFC| >2 were set as the cut-off criteria. Common DEGs from the three datasets were selected for functional annotation.

Functional and pathway enrichment analysis

The GO (http://www.geneontology.org) database includes three categories: biological process (BP), cellular component (CC), and molecular function (MF).Citation14 The KEGG (http://www.genome.ad.jp/kegg/) database collects genomic, chemical, and systematic functional information.Citation15 The Database for Annotation, Visualization and Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov/) provides a set of functional annotation tools to analyze the biological roles of genes.Citation16 In this study, GO terms and KEGG pathways were analyzed using the DAVID online tool with the enrichment threshold of P<0.05.

PPI network construction and analysis of modules

The STRING database (http://string-db.org/) provides a significant association of protein–protein interactions (PPIs).Citation17 Cytoscape is used for the visual exploration of interaction networks.Citation18 In this study, DEG PPI networks were analyzed by the STRING database and subsequently visualized using Cytoscape. A combined score >0.9 was set as the cut-off criterion. A novel Cytoscape plugin CytoHubbaCitation19 was used to identify the hub genes by finding the intersection of the top 30 genes from 12 topological analysis methods. Then, Molecular Complex Detection (MCODE) was performed to screen modules of PPI networks with degree cut-off =2, node score cut-off =0.2, k-core =2, and max depth =100. The functional enrichment analysis of genes in the module was performed using DAVID. A P-value <0.05 was set as the cut-off criterion.

Validation of hub genes

The Gene Expression Profiling Interactive Analysis (GEPIA) database (http://gepia.cancer-pku.cn/) is a web-based tool to deliver fast and customizable functionalities based on The Cancer Genome Atlas (TCGA) and GTEx data.Citation20 In this study, we used the GEPIA database to validate the expression of hub genes identified in the PPI network and module, and analyze the association of their expression levels with LAC TNM stage. We selected P<0.05 and fold change >2 as a threshold.

Exploring cancer genomics data by cBioportal

The cBioPortal for Cancer Genomics (http://cbioportal.org) provides a resource for visualization and analyzing multidimensional cancer genomics data.Citation20 In the present study, alteration frequencies of hub genes were performed based on Mutation and DNA copy-number alterations in four selected lung cancer subtypes (Pan-Lung Cancer-TCGA, Nat Genet 2016; Lung Adenocarcinoma-TCGA, Provisional; Lung Squamous Cell Carcinoma-TCGA, Provisional; Small-Cell Lung Cancer, U Cologne, Nature 2015).

Survival analysis of DEGs

A Kaplan–Meier plotter (www.kmplot.com) was used to assess the effect of 54,675 genes on survival using 10,461 samples, including 5,143 breast, 1,816 ovarian, 2,437 lung, and 1,065 gastric cancer patients.Citation21 We further investigated whether the overexpression of hub genes was associated with overall survival using the Kaplan–Meier method with log-rank test. The HR with 95% CI and log-rank P-value were calculated. We selected P<0.05 as a threshold.

Results

DEG identification

A total of 2,623 DEGs were identified from the GSE18842, GSE21993 and GSE89039 datasets. Among them, 169 genes presented identical expression trends in all three datasets (), including 70 upregulated genes and 99 down-regulated genes in lung cancer tissues compared with normal tissues. A heat map demonstrated the significant differential distribution of the DEGs using data profile GSE18842 as a reference ().

Figure 1 Identification of DEGs in mRNA expression profiling datasets GSE18842, GSE21993, and GSE89039.

Notes: The areas of overlap meant the commonly DEGs.

Abbreviations: DEGs, differentially expressed genes.

Figure 1 Identification of DEGs in mRNA expression profiling datasets GSE18842, GSE21993, and GSE89039.Notes: The areas of overlap meant the commonly DEGs.Abbreviations: DEGs, differentially expressed genes.

Figure 2 Heatmap plot of the 169 overlapped DEGs between lung cancer and normal samples in dataset GSE18842.

Notes: Red represents higher expression and green represents lower expression.

Abbreviation: DEGs, differentially expressed genes.

Figure 2 Heatmap plot of the 169 overlapped DEGs between lung cancer and normal samples in dataset GSE18842.Notes: Red represents higher expression and green represents lower expression.Abbreviation: DEGs, differentially expressed genes.

Functional and pathway enrichment analysis

To further understand the function and mechanism of the identified DEGs, GO and KEGG enrichment analyses were performed using DAVID (). The upregulated genes were mainly associated with the BP terms mitotic nuclear division, cell division, chromosome segregation, and DNA replication, while the downregulated genes were mainly enriched in cell adhesion, inflammatory response, and immune response. Additionally, CC analysis showed that the upregulated genes were associated with chromosome, mid-body, nucleoplasm, and spindle microtubule, and the downregulated genes were mainly found in the extracellular region, proteinaceous extracellular matrix, integral component of plasma membrane, membrane raft, and extracellular space. Moreover, for upregulated genes, MF terms contained ATP binding, protein binding, microtubule motor activity, protein kinase activity, and protein serine/threonine kinase activity, while the downregulated genes were relevant to heparin binding, flavin adenine dinucleotide binding, integrin binding, carbohydrate binding, and ion channel binding. DEGs, such as AURKB, KIF2C, BUB1B, CENPF, and CENPU, were discovered in the GO term analysis.

Table 1 Functional and pathway enrichment analysis of upregulated and downregulated genes in lung cancer

Furthermore, three KEGG pathways were significantly correlated with upregulated genes, including cell cycle, p53 pathway, and extracellular matrix (ECM)–receptor interaction, while two pathways were significantly related to the downregulated genes: PPAR pathway and tyrosine metabolism. Cell cycle-related genes, such as CCNB1, CDK1, and BUB1B, were identified in this KEGG analysis. DEGs including COL11A1, SPP1, and HMMR were identified in the ECM–receptor interaction pathway.

The DEG PPI network consisted of 71 nodes and 305 edges, including 49 upregulated genes and 22 downregulated genes (). A total of 12 hub genes were selected by the intersection of the top 30 genes from 12 algorithms using CytoHubba, including AURKB, KIF2C, NDC80, BUB1B, CDCA8, NUSAP1, CENPF, CENPU, MELK, CDKN3, PBK, and HMMR. A significant module was obtained from the DEG PPI network using MCODE, including 19 nodes and 143 edges (). Functional and KEGG pathway enrichment analyses revealed that genes in this module were mainly associated with cell cycle and p53 pathway (). Furthermore, we found that AURKB, KIF2C, BUB1B, HMMR, CENPF, and CENPU were involved in the GO, KEGG, and module analyses.

Figure 3 (A) PPI network of DEGs, (B) A significant module selected from PPI network.

Notes: (A) Red nodes stand for upregulated genes, while green nodes stand for downregulated genes. The larger the size, the greater the gene is differentially expressed between the lung cancer and normal tissue samples. (B) The red lines represent strong interaction relationship between nodes, while green lines represent weak relationship.

Abbreviations: DEGs, differentially expressed genes; PPI, protein–protein interaction.

Figure 3 (A) PPI network of DEGs, (B) A significant module selected from PPI network.Notes: (A) Red nodes stand for upregulated genes, while green nodes stand for downregulated genes. The larger the size, the greater the gene is differentially expressed between the lung cancer and normal tissue samples. (B) The red lines represent strong interaction relationship between nodes, while green lines represent weak relationship.Abbreviations: DEGs, differentially expressed genes; PPI, protein–protein interaction.

Figure 4 The bar plot showing the enrichment scores (−log10[P-value]) of the significant enrichment GO terms and KEGG pathways in module.

Notes: If there were more than five terms enriched in this category, top five terms were selected according to P-value. (A) Enrichment of BP; (B) enrichment of CC; (C) enrichment of MF; (D) KEGG pathways.

Abbreviations: BP, biological process; CC, cellular component; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MF, molecular function.

Figure 4 The bar plot showing the enrichment scores (−log10[P-value]) of the significant enrichment GO terms and KEGG pathways in module.Notes: If there were more than five terms enriched in this category, top five terms were selected according to P-value. (A) Enrichment of BP; (B) enrichment of CC; (C) enrichment of MF; (D) KEGG pathways.Abbreviations: BP, biological process; CC, cellular component; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MF, molecular function.

Validation of hub genes

Hub genes were further validated using the GEPIA database. GEPIA provides box plots, violin plots based on pathological stages, dot plots, and matrix plots in the “Expression DIY” tab. Consistent with the GEO analysis, GEPIA box plots of key gene expression levels showed that six hub genes were overexpressed in lung cancer samples compared with normal tissues (). In addition, GEPIA violin plots of gene expression by pathological stages based on the TCGA clinical annotation revealed their high expression levels significantly associated with advanced TNM stage (P-value <0.05) ().

Figure 5 GEPIA boxed plots of key genes (A) CENPF; (B) KIF2C; (C) AURKB; (D) BUB1B; (E) CENPU; (F) HMMR in human LAC and normal lungs.

Notes: *P<0.05.

Abbreviations: GEPIA, Gene Expression Profiling Interactive Analysis; LAC, lung adenocarcinoma.

Figure 5 GEPIA boxed plots of key genes (A) CENPF; (B) KIF2C; (C) AURKB; (D) BUB1B; (E) CENPU; (F) HMMR in human LAC and normal lungs.Notes: *P<0.05.Abbreviations: GEPIA, Gene Expression Profiling Interactive Analysis; LAC, lung adenocarcinoma.

Figure 6 GEPIA violin plots based on pathological stages (A) CENPF; (B) KIF2C; (C) AURKB; (D) BUB1B; (E) CENPU; (F) HMMR in human LAC.

Abbreviations: GEPIA, Gene Expression Profiling Interactive Analysis; LAC, lung adenocarcinoma.

Figure 6 GEPIA violin plots based on pathological stages (A) CENPF; (B) KIF2C; (C) AURKB; (D) BUB1B; (E) CENPU; (F) HMMR in human LAC.Abbreviations: GEPIA, Gene Expression Profiling Interactive Analysis; LAC, lung adenocarcinoma.

Genomic alterations of hub genes

We used cBioportal tool to explore the specific alterations of hub genes in four selected lung cancer datasets with 1,662 samples. From the OncoPrint, percentages of alterations in AURKB, KIF2C, BUB1B, HMMR, CENPF, and CENPU genes among lung cancer ranged from 1.3% to 9% in individual genes (AURKB, 1.3%; KIF2C, 2.1%; BUB1B, 3%; HMMR, 1.9%; CENPF, 9%; CENPU, 4%) (). In addition, cancer type summary analysis showed that the ratio of alteration of six genes varied from 5.45% to 21.24%, with lowest to highest level as small-cell lung cancer, lung squamous cell carcinoma, and LAC in four lung cancer datasets (). Further, the graphical summary of mutations showed that there were 113 CENPF nonsynonymous mutations in lung cancer samples, and 3 of them were S2021C/F in the CENPF domain (). There were six CENPU nonsynonymous mutations in lung cancer samples, two of them being E314K/V in the CENPU domain ().

Figure 7 Matrix heatmap shows genomic alterations of hub genes in four selected lung datasets (Pan-Lung Cancer-TCGA, Nat Genet 2016; Lung Adenocarcinoma-TCGA, Provisional; Lung Squamous Cell Carcinoma-TCGA, Provisional; Small Cell Lung Cancer, U Cologne, Nature 2015).

Notes: Each row represents a gene, and each column represents a tumor sample. Red bars indicate gene amplifications, blue bars are deep deletion, green squares are missense mutation, and red bars indicate no alterations. Downloaded from cBioPortal for Cancer Genomics (http://cbioportal.org).Citation20,Citation60

Abbreviation: TCGA, The Cancer Genome Atlas.

Figure 7 Matrix heatmap shows genomic alterations of hub genes in four selected lung datasets (Pan-Lung Cancer-TCGA, Nat Genet 2016; Lung Adenocarcinoma-TCGA, Provisional; Lung Squamous Cell Carcinoma-TCGA, Provisional; Small Cell Lung Cancer, U Cologne, Nature 2015).Notes: Each row represents a gene, and each column represents a tumor sample. Red bars indicate gene amplifications, blue bars are deep deletion, green squares are missense mutation, and red bars indicate no alterations. Downloaded from cBioPortal for Cancer Genomics (http://cbioportal.org).Citation20,Citation60Abbreviation: TCGA, The Cancer Genome Atlas.

Figure 8 The alteration frequencies of hub genes across four different cancer studies.

Notes: (A) A histogram of the alteration frequencies of hub genes across four lung cancer datasets (Pan-Lung Cancer-TCGA, Nat Genet 2016; Lung Adenocarcinoma-TCGA, Provisional; Lung Squamous Cell Carcinoma-TCGA, Provisional; Small Cell Lung Cancer, U Cologne, Nature 2015). (B) Mutation diagram of CENPF in different cancer types across protein domains in lung cancer across protein domains. (C) Mutation diagram of CENPU mutations in lung cancer across protein domains. Downloaded from cBioPortal for Cancer Genomics (http://cbioportal.org).Citation20,Citation60

Abbreviations: CENPF, Centromere Protein; CENPU, Centromere Protein U; TCGA, The Cancer Genome Atlas.

Figure 8 The alteration frequencies of hub genes across four different cancer studies.Notes: (A) A histogram of the alteration frequencies of hub genes across four lung cancer datasets (Pan-Lung Cancer-TCGA, Nat Genet 2016; Lung Adenocarcinoma-TCGA, Provisional; Lung Squamous Cell Carcinoma-TCGA, Provisional; Small Cell Lung Cancer, U Cologne, Nature 2015). (B) Mutation diagram of CENPF in different cancer types across protein domains in lung cancer across protein domains. (C) Mutation diagram of CENPU mutations in lung cancer across protein domains. Downloaded from cBioPortal for Cancer Genomics (http://cbioportal.org).Citation20,Citation60Abbreviations: CENPF, Centromere Protein; CENPU, Centromere Protein U; TCGA, The Cancer Genome Atlas.

Survival analysis of DEGs

Finally, overall survival analysis of hub genes was performed using the Kaplan–Meier plotter online tool. The results showed that high AUARB mRNA expression (HR =1.84 [1.62–2.1], log-rank P<1×10−16) was associated with worse overall survival for lung cancer patients, as were KIF2C (HR =1.78 [1.57–2.03], log-rank P<1×10−16), BUB1B (HR =1.71 [1.5–1.94], log-rank P=2.2×10−16), HMMR (HR =1.44 [1.27–1.64], log-rank P=1.5×10−08), CENPF (HR =1.57 [1.38–1.78], log-rank P=3.4×10−12), and CENPU (HR =1.86 [1.58–2.21], log-rank P=1.5×10−13) ().

Figure 9 Prognostic value of six key genes (A: KIF2C; B: AURKB; C: HMMR; D: BUB1B; E: CENPF; F: CENPU) in lung cancer patients from TCGA and GEO database.

Notes: Log-rank test was performed to evaluate the survival differences between the two curves.

Abbreviations: GEO, Gene Expression Omnibus; TCGA, The Cancer Genome Atlas.

Figure 9 Prognostic value of six key genes (A: KIF2C; B: AURKB; C: HMMR; D: BUB1B; E: CENPF; F: CENPU) in lung cancer patients from TCGA and GEO database.Notes: Log-rank test was performed to evaluate the survival differences between the two curves.Abbreviations: GEO, Gene Expression Omnibus; TCGA, The Cancer Genome Atlas.

Discussion

In this study, we identified significant DEGs between LAC and normal samples. Furthermore, we performed a series of bioinformatics analysis to screen key genes and pathways.

A total of 169 DEGs were found, consisting of 70 upregulated genes and 99 downregulated genes. The upregulated genes were mainly enriched in cell cycle, p53 pathway, and ECM–receptor interaction, which are closely related to cancer, while the downregulated genes were mainly associated with PPAR pathway and tyrosine metabolism. Among these DEGs, the top 12 hub genes selected in the PPI network were all overexpressed. Functional and pathway enrichment analyses revealed that the 19 genes in the significant module were mainly enriched in cell cycle, progesterone-mediated oocyte maturation, p53 pathway, and oocyte meiosis.

Based on these findings, DEGs including AURKB, KIF2C, BUB1B, HMMR, CENPF, and CENPU were identified in these functions. These genes were also hub nodes in PPI networks. Then, we found the expression of six key genes in LAC were higher than in control group, and their high expression levels were significantly associated with advanced TNM stage using the GEPIA database. Furthermore, we applied cBioPortal web recourse to explore the genomic alterations of hub genes in lung cancer cases from TCGA databases. We found hub genes mutation frequencies were the highest in LAC. CENPF and CENPU have higher alteration frequency of 4% and 9%, respectively, compared with other hub genes in lung cancer samples. Two hotspot mutations (S2021C/F and E314K/V) were identified in Pfam protein domains, illustrating that these may be potential targets for lung cancer.

Finally, survival analysis of these six key genes showed that these genes were significantly associated with worse overall survival in lung cancer patients. Thus, these DEGs and their related functions may be involved in the development and progression of lung cancer.

Aurora Kinase B (AURKB) is a critical regulator of mitosis that belongs to a new family of serine/threonine kinases.Citation22 Aurora B provides catalytic activity to the chromosome passenger complex. Overexpression of an inactive form of Aurora B results in multinucleation and polyploidy, and tetraploidy has been shown to increase the frequency of chromosomal alterations and promote tumorigenesis of p53-deficient cells. In this study, we show that AURKB upregulation was associated with poor prognosis in lung cancer. Consistently, previous studies have identified an association between AURKB expression and lung cancer progression. Hayama et alCitation23 demonstrated that AURKB overexpression promotes lung carcinogenesis and increases invasiveness in vivo. Additionally, Takeshita et al reported that AURKB overexpression was correlated with aneuploidy and poor prognosis in NSCLC.Citation24 Another recent study showed that AURKB was an important KRAS target in lung cancer, suggesting that AURKB inhibition could be a novel approach for KRAS-driven lung cancer therapy.Citation25 Moreover, Al-Khafaji et alCitation26 revealed that AURKB activity is an important modulator of taxane response in NSCLC cells. Therefore, we speculate that AURKB may play an important role in the progression of lung cancer as a regulator of mitotic spindle assembly, and thus may be a potential therapeutic target for lung cancer.

Kinesin Family Member 2C (KIF2C) also known as mitotic centromere associated kinesin, is a member of the kinesin family of microtubule motor proteins that stimulates microtubule depolymerization and ensures proper chromosome segregation during mitosis.Citation27 The abnormal expression of KIF2C is associated with abnormal mitosis, chromosomal aberrations, and malignant transformation. Therefore, the deregulation of KIF2C expression can contribute to cancer development and progression. Previous studies have suggested that KIF2C overexpression is associated with tumor progression in esophageal squamous cell carcinoma,Citation28 breast cancer,Citation29 colorectal cancer,Citation30,Citation31 gastric cancer,Citation32 and glioma.Citation33 However, there is little data for KIF2C in lung cancer. Bidkhori et alCitation34 reported that KIF2C overexpression is connected with tumor progression in LAC using an integrated genome-scale coexpression network. In this study, we found that KIF2C was involved in the GO BP terms mitotic nuclear division, cell division, and sister chromatid cohesion. It is evident that cell cycle regulatory factors play an important role in cancer development. Uncontrolled cell proliferation is common to patients with different types of cancer. KIF2C overexpression was significantly associated with poor prognosis in lung cancer patients. These observations suggest that KIF2C may be a cell cycle regulatory factor with therapeutic potential for lung cancer treatment.

BUB1 Mitotic Checkpoint Serine/Threonine Kinase B (BUB1B) is a key component of the spindle assembly checkpoint that is required for accurately segregating chromosomes based on its function in the mitotic checkpoint and the establishment of proper microtubule–kinetochore attachments.Citation35 The function of BUB1B in mitosis includes activation, maintenance, and silencing the spindle assembly checkpoint as well as regulating chromosome–spindle attachment, and it is also required for controlling mitotic timing. Aberrant expression or mutations of BUB1B can cause aneuploidy. Several studies have revealed that BUB1B overexpression is associated with the progression and recurrence of bladder cancer,Citation36 gastric cancer,Citation37 breast cancer,Citation38,Citation39 prostate cancer,Citation40 and other malignancies. There is currently no clear evidence for the relationship between BUB1B and lung cancer. Chen et alCitation41 reported that BUB1B overexpression is associated with disease progression and poor survival in human LAC patients from TCGA project. In this study, we found that BUB1B was enriched in cell cycle pathway. Cell cycle dysregulation underlies the aberrant cell proliferation that characterizes cancer, and the loss of cell cycle checkpoint control promotes genetic instability. BUB1B was highly expressed in lung cancer and markedly correlated with poor prognosis in accordance with previous findings. Thus, our findings suggest that BUB1B may be a promising diagnostic and therapeutic target in lung cancer.

Hyaluronan Mediated Motility Receptor (HMMR) also known as RHAMM and IHABP, is a multifunctional protein with both intracellular and extracellular roles in cell motility and proliferation. Previous studies have indicated that HMMR expression was elevated in most human cancers, and is linked to aggressive disease and poor clinical outcomes in breast cancer,Citation42 prostate cancer,Citation43 bladder cancer,Citation44 acute myeloid leukemia,Citation45 gastric cancer,Citation46 and cervical cancer.Citation47 Recently, Wang et alCitation48 reported that RHAMM expression correlates with poor prognosis and metastasis in NSCLC; Stevens et alCitation49 revealed upregulated HMMR potentiates lung and brain metastatic outgrowths through coopting inflammatory ECM components in dissemination-competent LAC cells. Consistent with previous studies, we found that HMMR overexpression was significantly associated with poor clinical outcomes. Additionally, HMMR was enriched in the ECM–receptor interaction pathway. This evidence suggested that HMMR may play an important role in lung cancer progression.

Centromere Protein F (CENPF) is a member of the centromere protein family and plays an important role in critical chromosomal segregation processes. CENPF is dynamically expressed throughout the cell cycle. Accumulating evidence has shown that CENPF overexpression is associated with cancer progression and prognosis in prostate cancer,Citation50 breast cancer,Citation51 hepatocellular carcinoma,Citation52 esophageal squamous cell carcinoma,Citation53 and nasopharyngeal carcinoma.Citation54 Andriani et alCitation55 reported that lung cancers with both FHIT and p53 inactivation displayed high levels of CENPF expression. However, the oncogenic role and clinical significance of CENPF in lung cancer have not been adequately explored. In this study, we found that CENPF was associated with the GO BP terms mitotic nuclear division, cell division, chromosome segregation, and sister chromatid cohesion. Furthermore, we demonstrated that CENPF was highly expressed in lung cancer and significantly related to poor clinical outcomes, suggesting a potential role in tumorigenesis.

Centromere Protein U (CENPU), also known as MLF1IP, is a transcription suppressor that is also required for proper chromosome segregation. CENPU plays an important role in assembly of kinetochore proteins, mitotic progression, and chromosome segregation. Studies have revealed that CENPU upregulation is correlated with progression and prognosis in luminal breast cancer,Citation56 familial colorectal cancer,Citation57 and bladder cancer.Citation58 Additionally, CENPU promotes prostate cancer cell proliferation and colony formation and significantly inhibits apoptosis; however, no clear change in CENPU expression has been identified.Citation59 Moreover, no data are available regarding the oncogenic role and clinical significance of CENPU in lung cancer. In this study, we found that CENPU was associated with the GO BP term sister chromatid cohesion, and CENPU overexpression was significantly associated with poor prognosis in lung cancer. These observations suggested that CENPU abnormalities may contribute to the risk of developing lung cancer.

Conclusion

Compared with previous studies, this study identified several novel genes with prognostic value involved in LAC, such as KIF2C, CENPF and CENPU. These genes could potentially be used in the molecular diagnosis or treatment of LAC. Nevertheless, further investigations are required to establish the mechanisms of these genes in LAC.

Disclosure

The authors report no conflicts of interest in this work.

References

  • SiegelRLMillerKDJemalACancer Statistics, 2017CA Cancer J Clin201767173028055103
  • IARC Working Group on the Evaluation of Carcinogenic Risks to HumansPersonal habits and indoor combustions. Volume 100 E. A review of human carcinogensIARC Monogr Eval Carcinog Risks Hum2012100Pt E1538
  • HamraGBGuhaNCohenAOutdoor particulate matter exposure and lung cancer: a systematic review and meta-analysisEnviron Health Perspect2014122990691124911630
  • SatoMShamesDSGazdarAFMinnaJDA translational view of the molecular pathogenesis of lung cancerJ Thorac Oncol20072432734317409807
  • SaitoMShiraishiKKunitohHTakenoshitaSYokotaJKohnoTGene aberrations for precision medicine against lung adenocarcinomaCancer Sci2016107671372027027665
  • XuCWCaiXYShaoYA case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature reviewMol Med Rep20151234370437526130140
  • PascheBGrantSCNon-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial designJAMA2014311191975197624846033
  • MillerKDSiegelRLLinCCCancer treatment and survivorship statistics, 2016CA Cancer J Clin201666427128927253694
  • ShiRZhangCWuYCDCA2 promotes lung adenocarcinoma cell proliferation and predicts poor survival in lung adenocarcinoma patientsOncotarget2017812197681977928423619
  • ZhangYHeRQDangYWComprehensive analysis of the long noncoding RNA HOXA11-AS gene interaction regulatory network in NSCLC cellsCancer Cell Int2016168927980454
  • LiGGaoYCuiYOverexpression of CD44 is associated with the occurrence and migration of non-small cell lung cancerMol Med Rep20161443159316727573351
  • CamidgeDRPaoWSequistLVAcquired resistance to TKIs in solid tumours: learning from lung cancerNat Rev Clin Oncol201411847348124981256
  • BarrettTWilhiteSELedouxPNCBI GEO: archive for functional genomics data sets--updateNucleic Acids Res201341Database issueD99199523193258
  • AshburnerMBallCABlakeJAGene ontology: tool for the unification of biology. The Gene Ontology ConsortiumNat Genet2000251252910802651
  • KanehisaMSatoYKawashimaMFurumichiMTanabeMKEGG as a reference resource for gene and protein annotationNucleic Acids Res201644D1D457D46226476454
  • DennisGShermanBTHosackDADAVID: Database for Annotation, Visualization, and Integrated DiscoveryGenome Biol200345P312734009
  • SzklarczykDFranceschiniAKuhnMThe STRING database in 2011: functional interaction networks of proteins, globally integrated and scoredNucleic Acids Res201139Database issueD561D56821045058
  • SmootMEOnoKRuscheinskiJWangPLIdekerTCytoscape 2.8: new features for data integration and network visualizationBioinformatics201127343143221149340
  • ChinCHChenSHWuHHHoCWKoMTLinCYcytoHubba: identifying hub objects and sub-networks from complex interactomeBMC Syst Biol20148Suppl 4S1125521941
  • GaoJAksoyBADogrusozUIntegrative analysis of complex cancer genomics and clinical profiles using the cBioPortalSci Signal20136269pl123550210
  • GyorffyBLánczkyASzállásiZImplementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patientsEndocr Relat Cancer201219219720822277193
  • GoldensonBCrispinoJDThe aurora kinases in cell cycle and leukemiaOncogene201534553754524632603
  • HayamaSDaigoYYamabukiTPhosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesisCancer Res20076794113412217483322
  • TakeshitaMKogaTTakayamaKAurora-B overexpression is correlated with aneuploidy and poor prognosis in non-small cell lung cancerLung Cancer2013801859023313006
  • dos SantosEOCarneiro-LoboTCAokiMNLevantiniEBassèresDSAurora kinase targeting in lung cancer reduces KRAS-induced transformationMol Cancer2016151226842935
  • Al-KhafajiASDaviesMPRiskJMAurora B expression modulates paclitaxel response in non-small cell lung cancerBr J Cancer2017116559259928095398
  • WordemanLWagenbachMvon DassowGMCAK facilitates chromosome movement by promoting kinetochore microtubule turnoverJ Cell Biol2007179586987918039936
  • DuanHZhangXWangFXKIF-2C expression is correlated with poor prognosis of operable esophageal squamous cell carcinoma male patientsOncotarget2016749804938050727563815
  • ShimoATanikawaCNishidateTInvolvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesisCancer Sci2008991627017944972
  • GnjaticSCaoYReicheltUNY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancerInt J Cancer2010127238139319937794
  • IshikawaKKamoharaYTanakaFMitotic centromere-associated kinesin is a novel marker for prognosis and lymph node metastasis in colorectal cancerBr J Cancer200898111824182918506187
  • NakamuraYTanakaFHaraguchiNClinicopathological and biological significance of mitotic centromere-associated kinesin overexpression in human gastric cancerBr J Cancer200797454354917653072
  • BieLZhaoGWangYPZhangBKinesin family member 2C (KIF2C/MCAK) is a novel marker for prognosis in human gliomasClin Neurol Neurosurg2012114435636022130050
  • BidkhoriGNarimaniZHosseini AshtianiSMoeiniANowzari-DaliniAMasoudi-NejadAReconstruction of an integrated genome-scale co-expression network reveals key modules involved in lung adenocarcinomaPLoS One201387e6755223874428
  • BakerDJDawlatyMMWijshakeTIncreased expression of BubR1 protects against aneuploidy and cancer and extends healthy lifespanNat Cell Biol20131519610223242215
  • YamamotoYMatsuyamaHChochiYOverexpression of BUBR1 is associated with chromosomal instability in bladder cancerCancer Genet Cytogenet20071741424717350465
  • AndoKKakejiYKitaoHHigh expression of BUBR1 is one of the factors for inducing DNA aneuploidy and progression in gastric cancerCancer Sci2010101363964520132214
  • MansouriNMovafaghASayadATargeting of BUB1b Gene Expression in Sentinel Lymph Node Biopsies of Invasive Breast Cancer in Iranian Female PatientsAsian Pac J Cancer Prev201617S331732127165245
  • MukherjeeAJosephCCrazeMChrysanthouEEllisIOThe role of BUB and CDC proteins in low-grade breast cancersLancet2015385Suppl 1S7226312894
  • FuXChenGCaiZDOverexpression of BUB1B contributes to progression of prostate cancer and predicts poor outcome in patients with prostate cancerOnco Targets Ther201692211222027143916
  • ChenHLeeJKljavinNMRequirement for BUB1B/BUBR1 in tumor progression of lung adenocarcinomaGenes Cancer201563–410611826000094
  • SchwertfegerKLCowmanMKTelmerPGTurleyEAMccarthyJBHyaluronan, Inflammation, and Breast Cancer ProgressionFront Immunol2015623626106384
  • KorkesFde CastroMGde Cassio ZequiSNardiLdel GiglioAde Lima PompeoACHyaluronan-mediated motility receptor (RHAMM) immunohistochemical expression and androgen deprivation in normal peritumoral, hyperplasic and neoplastic prostate tissueBJU Int2014113582282924053431
  • NiedworokCKretschmerIRöckKThe impact of the receptor of hyaluronan-mediated motility (RHAMM) on human urothelial transitional cell cancer of the bladderPLoS One201389e7568124069434
  • TzankovAStrasserUDirnhoferSIn situ RHAMM protein expression in acute myeloid leukemia blasts suggests poor overall survivalAnn Hematol201190890190921274712
  • IshigamiSUenoSNishizonoYPrognostic impact of CD168 expression in gastric cancerBMC Cancer20111110621435222
  • Villegas-RuízVSalcedoMZentella-DehesaAA case of cervical cancer expressed three mRNA variant of Hyaluronan-mediated motility receptorInt J Clin Exp Pathol2014752256226424966934
  • WangDNarulaNAzzopardiSExpression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinomaOncotarget2016726399573996927220886
  • StevensLECheungWKCAduaSJExtracellular Matrix Receptor Expression in Subtypes of Lung Adenocarcinoma Potentiates Outgrowth of MicrometastasesCancer Res20177781905191728196904
  • ZhuoYJXiMWanYPEnhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancerInt J Mol Med201535496697225647485
  • O’BrienSLFaganAFoxEJCENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancerInt J Cancer200712071434144317205517
  • DaiYLiuLZengTCharacterization of the oncogenic function of centromere protein F in hepatocellular carcinomaBiochem Biophys Res Commun2013436471171823791740
  • MiYJGaoJXieJDPrognostic relevance and therapeutic implications of centromere protein F expression in patients with esophageal squamous cell carcinomaDis Esophagus201326663664323163484
  • CaoJYLiuLChenSPPrognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinomaMol Cancer2010923720828406
  • AndrianiFRozECaseriniRInactivation of both FHIT and p53 cooperate in deregulating proliferation-related pathways in lung cancerJ Thorac Oncol20127463164222425911
  • HuangDPLuoRCMLF1IP is correlated with progression and prognosis in luminal breast cancerBiochem Biophys Res Commun2016477492392627378428
  • Dominguez-ValentinMTherkildsenCVeerlaSDistinct gene expression signatures in lynch syndrome and familial colorectal cancer type xPLoS One201388e7175523951239
  • WangSLiuBZhangJCentromere protein U is a potential target for gene therapy of human bladder cancerOncol Rep201738273574428677729
  • ZhangLJiGShaoYMLF1 interacting protein: a potential gene therapy target for human prostate cancer?Med Oncol201532245425572810
  • CeramiEGaoJDogrusozUThe cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics dataCancer Discov20122540140422588877